NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 127 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $65 | – | 12,885 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 16,245,817 | $247,749,000 | 45.93% |
| Ponoi II Management, LLC | 1,298,908 | $19,808,000 | 43.96% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $57,442,000 | 39.74% |
| Ponoi Management, LLC | 1,298,908 | $19,808,000 | 25.71% |
| Euclidean Capital LLC | 746,674 | $11,387,000 | 6.62% |
| StepStone Group LP | 1,573,357 | $23,994,000 | 1.79% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 200,494 | $3,058,000 | 1.26% |
| First Light Asset Management, LLC | 816,653 | $12,454,000 | 1.10% |
| BVF INC/IL | 955,000 | $14,564,000 | 0.58% |
| HighVista Strategies LLC | 46,243 | $705,000 | 0.45% |